COLA: Rhinitis

Session recorded on August 21, 2017.

Speaker: Mark S. Dykewicz, MD

Viewers can earn credit by completing the posttest questions.

New evidence based rhinitis treatment guidelines in press by (1) Joint Task Force for Practice Parameters of AAAAI and ACAAI and (2) ARIA, both based upon GRADE analysis (Grading of Recommendations, Assessment, Development and Evaluations) need to be disseminated. Recommendations include discouraging use of commonly used treatment strategies (e.g. combination of oral antihistamine and intranasal corticosteroids) for which there is little evidence basis. These new recommendations need to presented in broader context of available knowledge and treatment options. This video covers the defintion and importance of rhinitis. It covers allergic and non-allergic rhinitis, along with differential considerations, diagnosis, and treatment.

Target Audience

Practicing Allergists / Immunologists
Fellows-in-Training

Learning Objectives

After viewing the video recording, learners should be able to…

  • Distinguish between allergic and non-allergic forms of rhinitis, and differential considerations
  • Select pharmacologic monotherapy and combination therapy for allergic and non-allergic rhinitis
  • Describe process and deliberations used to establish recent evidence-based guideline recommendations for rhinitis
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity.

Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Jay Portnoy, MD, Planner
Speaker, Honorarium: Thermofisher, Boehringer Ingelheim

The following have no financial relationships to disclose:

Paul Dowling, MD, Planner
Mark S. Dykewicz, MD, Speaker

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
08/29/2017
Course expires: 
08/28/2019
Cost:
$35.00
Rating: 
0

Mark S. Dykewicz, MD
Raymond & Alberta Slavin Endowed Professor in Allergy & Immunology
Professor of Internal Medicine
Chief, Section of Allergy and Immunology
Division of Infectious Diseases, Allergy & Immunology
Department of Internal Medicine
Director, Allergy and Immunology Fellowship Program
Saint Louis University

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
There is no commercial support for this activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Accreditation Period

Course opens: 
08/29/2017
Course expires: 
08/28/2019

Price

Cost:
$35.00
Please login or create an account to take this course.